ARLINGTON, TN, November 21, 2025 /24-7PressRelease/ -- Divyen Patel, PhD, has been included in Marquis Who's Who. As in all Marquis Who's Who biographical volumes, individuals profiled are selected on the basis of current reference value. Factors such as position, noteworthy accomplishments, visibility, and prominence in a field are all taken into account during the selection process.

Dr. Patel has established a distinguished career at the intersection of genomics, cancer research and biotechnology innovation. As the founder and chief executive officer of Genome Explorations since 2001, he has developed a robust research pipeline that has produced more than 180 peer-reviewed publications, each serving as proof of concept for novel diagnostics with potential therapeutic applications. Under his leadership, Genome Explorations became the first genomic company to provide research services to institutions worldwide, emerging shortly after the sequencing of the human genome. The company was founded from St. Jude Children's Research Hospital, leveraging foundational tools for profiling cancers to design precision treatments for individual patients.

Within its first year, Genome Explorations secured clients such as Harvard University, University of Oxford, University of Cambridge, the Louis Pasteur Institute in France, the Hong Kong Institute of Technology and the Indian Institute of Technology, demonstrating an extensive global reach. Dr. Patel guided the company's international expansion by establishing subsidiaries in Hyderabad, India and Bordeaux, France, to serve European clients, as well as a subsidiary in Sheffield, United Kingdom, to capture the UK and Irish markets. Notably, Dr. Patel managed these accomplishments without venture capital support.

Dr. Patel's approach to disease research is characterized by global genomic profiling methods that uncover underlying causes of several devastating diseases and guide personalized treatments. He introduced a novel methodology that led to a contract with the Department of Defense for developing a blood based test to definitively differentiate traumatic brain injury and PTSD with an 87 percent reproducibility rate and 99 percent accuracy. Genome Explorations has expanded its focus beyond cancer to include Alzheimer's disease, traumatic brain injuries and other conditions, aiming to identify root causes and potential treatment methods. Each sample processed by Dr. Patel's company undergoes between 2.7 million and 3.2 billion tests, reflecting a rigorous high-throughput approach.

Genome Explorations and Dr. Patel have been awarded numerous national and international awards and press releases recognizing the vast number of contributions to Healthcare made over the past 25 years.

Before launching Genome Explorations, Dr. Patel served as the director of the microarray facility at St. Jude Children's Research Hospital from 1995 to 2001. In this capacity, he played a pivotal role in advancing cancer research technologies that are now used to guide personalized treatments and have contributed to raising cure rates from 60 percent to 90 percent. Dr. Patel held concurrent roles as the director from 1993 to 2001 and the division director from 1992 to 2001 at St. Jude Children's Research Hospital, where he was instrumental in developing innovative diagnostic platforms and collaborating with leading scientists on disease-focused projects.

Dr. Patel's academic achievements include a Bachelor of Science in biochemistry from Liverpool John Moores University, completed in 1987, and a Doctor of Philosophy in clinical medicine and molecular biology from the University of Leeds in England, conferred in 1992. During his graduate studies at Leeds, Dr. Patel proudly published 15 papers on cancer and leukemia—an accomplishment that led to his invitation by St. Jude Children's Research Hospital to contribute to advancing cancer research in the United States.

Driven by a passion for scientific discovery and innovation that benefits many, Dr. Patel works closely with colleagues ranging from professors to chief scientists in biotechnology, engaging in personal discussions to understand their goals and designing customized projects and protocols tailored to specific needs. He is recognized for his dedication, inquisitiveness and collaborative spirit, as well as his enduring commitment to rigorous quality control measures, which have enabled Dr. Patel to persist in developing efficient and effective processes.

Throughout his career, Dr. Patel has been featured in various international and local publications for his contributions to science and business innovation, and he has accepted both Businessman of the Year and Innovative Contributor of the Year awards. In addition to his professional pursuits, he regularly seeks opportunities for civic engagement and volunteers to assist colleagues and physicians by reviewing cases, supporting diagnostic processes and developing treatment plans. Dr. Patel also partners with physicians to ensure patients receive the highest quality of care.

Dr. Patel was born in Kampala into an internationally oriented family; his father worked as an international banker and served as the bank manager of Uganda's only international bank before relocating the family to England under a five-year permit while seeking a replacement manager. His younger brothers have also achieved success in technology careers with Oracle Corporation and Motorola Solutions. To achieve balance, Dr. Patel composes music and sings with his band, and he enjoys cooking.

Looking toward the future, Dr. Patel will remain committed to advancing scientific discovery through genomic technologies applied across a range of diseases while maintaining a long-term diversified pipeline focused on diagnostics and therapeutic solutions. Specifically, Dr. Patel plans to bring several innovative products to market: a blood-based biomarker test designed for definitive diagnosis of traumatic brain injury and post-traumatic stress disorder; a pan-genomic evaluation measuring individual responses to medications; a product derived from COVID-19 research identifying genetic mutations associated with severe outcomes or reduced symptom severity and designing panels for providing predisposition probabilities for up to but not limited to 88 different cancers.

About Marquis Who's Who®:
Since 1899, when A. N. Marquis printed the First Edition of Who's Who in America®, Marquis Who's Who® has chronicled the lives of the most accomplished individuals and innovators from every significant field of endeavor, including politics, business, medicine, law, education, art, religion and entertainment. Who's Who in America® remains an essential biographical source for thousands of researchers, journalists, librarians and executive search firms around the world. The suite of Marquis® publications can be viewed at the official Marquis Who's Who® website, www.marquiswhoswho.com.

# # #